1 Study Coverage
1.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2017-2022) & (US$ Million) Introduction
1.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Outlook 2017 VS 2022 VS 2028
1.2.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size for the Year 2017-2028
1.2.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size for the Year 2017-2028
1.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Dynamics
1.4.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Industry Trends
1.4.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Drivers
1.4.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Challenges
1.4.4 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Type
2.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segment by Type
2.1.1 Oral Therapy
2.1.2 Injectable Therapy
2.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017, 2022 & 2028)
2.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2028)
2.4 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017, 2022 & 2028)
2.5 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2028)
3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Application
3.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segment by Application
3.1.1 Hospitals & Clinics
3.1.2 Home Settings
3.1.3 Ambulatory Surgical Centers (ASCs)
3.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017, 2022 & 2028)
3.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2028)
3.4 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017, 2022 & 2028)
3.5 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2028)
4 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Competitor Landscape by Company
4.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Company
4.1.1 Top Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies Ranked by Revenue (2021)
4.1.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Player (2017-2022)
4.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Concentration Ratio (CR)
4.2.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in 2021
4.2.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Headquarters, Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2017-2022) & (US$ Million) Type
4.3.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Headquarters and Area Served
4.3.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Company
4.5.1 Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players in United States, Ranked by Revenue (2021)
4.5.2 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Players (2020, 2021 & 2022)
5 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region
5.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (2017-2028)
5.2.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region: 2017-2022
5.2.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth 2017-2028
6.1.2 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth 2017-2028
6.3.2 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth 2017-2028
6.4.2 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Astellas Inc.
7.1.1 Astellas Inc. Company Details
7.1.2 Astellas Inc. Business Overview
7.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
7.1.4 Astellas Inc. Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2017-2022)
7.1.5 Astellas Inc. Recent Development
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Company Details
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
7.2.4 Johnson & Johnson Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2017-2022)
7.2.5 Johnson & Johnson Recent Development
7.3 Sanofi S.A
7.3.1 Sanofi S.A Company Details
7.3.2 Sanofi S.A Business Overview
7.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
7.3.4 Sanofi S.A Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2017-2022)
7.3.5 Sanofi S.A Recent Development
7.4 Dendreon Corporation
7.4.1 Dendreon Corporation Company Details
7.4.2 Dendreon Corporation Business Overview
7.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
7.4.4 Dendreon Corporation Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2017-2022)
7.4.5 Dendreon Corporation Recent Development
7.5 Bayer AG
7.5.1 Bayer AG Company Details
7.5.2 Bayer AG Business Overview
7.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
7.5.4 Bayer AG Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2017-2022)
7.5.5 Bayer AG Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
